RxDoctor Payments Data

Ezekiel Duke, MD

Family Medicine · Abilene, TXNPI 1023193695

Payments from drug & device makers

$17,612in general payments, 2019–2025

Across 1,377 payments — averaging $12.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$2K
  • AstraZeneca$2K
  • GSK$2K
  • Lilly USA, LLC$1K
  • Amgen$1K
  • plus $7K from 44 others

What the payments were for

  • Food & beverage$17,541100%
  • Education$710%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,612 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$248,516
Medicare patients
367
Services billed
10,428

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide122$171,631
Trelegy ElliptaFluticasone/Umeclidin/Vilanter61$90,844
TrulicityDulaglutide37$73,455
JardianceEmpagliflozin56$70,335
MounjaroTirzepatide59$69,079
EliquisApixaban65$67,296
FarxigaDapagliflozin Propanediol33$50,090
Tresiba Flextouch U-200Insulin Degludec26$38,393
Repatha SureclickEvolocumab46$37,681
RybelsusSemaglutide16$25,581
LinzessLinaclotide29$25,426
Xigduo XrDapaglifloz Propaned/Metformin12$20,743
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$19,975
Tresiba Flextouch U-100Insulin Degludec29$15,555
MyrbetriqMirabegron11$14,359

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$2,409$197,211138 claims
Lilly USA, LLCTrulicity, Mounjaro$1,228$142,53496 claims
GSKTrelegy Ellipta, Shingrix$1,949$94,67378 claims
Boehringer IngelheimJardiance$421$70,33556 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,973$70,06546 claims
PfizerEliquis$760$67,29665 claims
AbbVieLinzess$2,282$25,42629 claims
Astellas Pharma US IncMyrbetriq$478$14,35911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Abilene

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →